Diversify Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 34,790 shares of the company's stock, valued at approximately $640,000.
A number of other institutional investors have also recently made changes to their positions in TEVA. New Covenant Trust Company N.A. purchased a new position in Teva Pharmaceutical Industries during the first quarter worth $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $30,000. UMB Bank n.a. boosted its stake in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after purchasing an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth about $48,000. Finally, Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter worth about $52,000. Institutional investors own 54.05% of the company's stock.
Teva Pharmaceutical Industries Stock Up 0.1 %
Shares of NYSE TEVA traded up $0.01 during midday trading on Friday, reaching $18.46. 7,100,133 shares of the company's stock traded hands, compared to its average volume of 9,285,298. The company has a market cap of $20.91 billion, a price-to-earnings ratio of -47.31, a P/E/G ratio of 1.34 and a beta of 0.88. The stock's 50 day simple moving average is $18.03 and its 200-day simple moving average is $16.89. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a one year low of $8.55 and a one year high of $19.08.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. The business had revenue of $4.16 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. On average, analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on TEVA shares. UBS Group upped their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Argus upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Wednesday, July 10th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and an average target price of $19.67.
Check Out Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
